Novartis joins Malaria No More in campaign to eliminate malaria

25 April 2013

Novartis and the charity Malaria No More have announced that they will work together to accelerate progress in the fight against malaria in a campaign called the Power of One.

Novartis will give financial support and donate up to three million courses of its paediatric antimalarial drug to match the treatments donated by the public.

The Power of One campaign aims to address the global treatment gap for malaria over three years through direct donations and existing government commitments. 

"We believe that this innovative campaign will help speed malaria elimination," said Joseph Jimenez, Novartis Chief Executive Officer. "Novartis has been striving towards this goal for more than a decade, and we just reached the milestone of providing 600 million treatments without profit to patients in malaria-endemic countries. No one should die from malaria today."

"The Power of One campaign challenges the global public to help close the global treatment gap for malaria; Every dollar raised will buy and deliver a full course of life-saving child treatment," said Martin Edlund, CEO of Malaria No More. "We are delighted to be partnering with forward-thinking companies like Novartis to help end deaths from this disease-one dollar and one child at a time."

Novartis has joined the Power of One campaign with some of the world's most innovative companies, including Alere who will be providing malaria rapid diagnostic tests, along with Time Warner, Twitter and others. The campaign will use the latest social, mobile, and e-commerce technologies to rally the global public to contribute to the campaign.

"Malaria is a complex issue and needs a multi-pronged collaborative approach. We can't solve a problem like this on our own," said Linus Igwemezie, Head of the Novartis Malaria Initiative. "Through partnerships, with organizations like Malaria No More, we can speed up progress toward the ultimate goal of malaria elimination."

Novartis reaches 600 million treatment deliveries

Power of One builds on the Novartis Malaria Initiative's efforts to eliminate malaria. Since 2001, a key focus of the company's commitment has been to supply its artemisinin-based combination therapy (ACT) to malaria-endemic countries. It has delivered 600 million ACT treatments without profit to the public sector of more than 60 malaria-endemic countries. This includes the provision of more than 150 million treatments of the antimalarial especially developed for children. Never before have so many treatments been distributed in such a short time frame to assist children suffering from malaria.
Novartis has two new classes of anti-malaria drugs in development. The most advanced compound is in Phase II clinical trials. For more information visit,

For more information about the Power of One campaign see



To top